Open Payments

TIMOTHY RODGERS

Type
Physician · Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology
Where
PROSPER, TX
NPI
1255395067
Received
$35,008 in 484 records, 2019 to 2025 ($11,692 general, $23,315 research)
As principal investigator
$951,959 of research payments to others in 321 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment92$1,805
2024General payment82$1,750
2023General payment69$2,925
2023Research payment1$5,750
2022General payment62$1,518
2022Research payment1$31
2021General payment47$969
2021Research payment2$5,172
2020General payment45$868
2020Research payment2$7,102
2019General payment79$1,853
2019Research payment2$5,260

By company

CompanyRecordsAmountYears
Eli Lilly and Company7$17,5652019–2022
PFIZER INC.42$7,6022019–2025
ABBVIE INC.101$1,8632019–2025
Amgen Inc.31$7852020–2025
Lilly USA, LLC39$7822019–2025
Allergan, Inc.36$6892019–2022
Novartis Pharmaceuticals Corporation28$6652019–2025
Janssen Biotech, Inc.23$6192019–2025
Regeneron Pharmaceuticals, Inc.2$5262019
MERZ NORTH AMERICA, INC.5$4712019–2022
Galderma Laboratories, L.P.31$4412019–2025
SUN PHARMACEUTICAL INDUSTRIES INC.20$4412019–2025
Arcutis Biotherapeutics, Inc.17$3452023–2025
Regeneron Healthcare Solutions, Inc.11$3392020–2025
Ortho Dermatologics, a division of Bausch Health US, LLC10$1932019–2023
Incyte Corporation10$1922023–2025
MAYNE PHARMA COMMERCIAL LLC10$1542020–2025
LEO Pharma Inc.7$1502022–2025
UCB, Inc.7$1472019–2025
Botanix SB Inc5$1072025
E.R. Squibb & Sons, L.L.C.5$912022–2024
Almirall LLC5$912022–2024
Sensus Healthcare, Inc.1$802019
Medimetriks Pharmaceuticals, Inc.1$802023
GENZYME CORPORATION3$732019–2024
Biofrontera Inc.3$682023–2025
Aclaris Therapeutics, Inc.3$562019
Dermavant Sciences, Inc.3$532023–2024
STRATA Skin Sciences, Inc.4$512021–2022
Acrotech Biopharma Inc.1$452022
Celgene Corporation2$362019
Boehringer Ingelheim Pharmaceuticals, Inc.1$242024
AngioDynamics, Inc.1$242023
Cipher Pharmaceuticals US LLC1$222025
Kerecis Limited1$202024
MIMEDX Group, Inc.1$202024
Journey Medical Corporation1$172022
VYNE Pharmaceuticals Inc.1$172020
Tactile Systems Technology Inc1$162023
DERMIRA, INC.1$142020
Nabriva Therapeutics, plc1$112021
Organon Llc1$22025

By nature of payment

NatureRecordsAmount
Research payment8$23,315
Food and Beverage470$10,611
Travel and Lodging3$969
Education3$111

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-16Galderma Laboratories, L.P.$16Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-12-16MAYNE PHARMA COMMERCIAL LLC$9Food and BeverageIn-kind items and services2025
2025-12-16MAYNE PHARMA COMMERCIAL LLC$0Food and BeverageIn-kind items and services2025
2025-12-16MAYNE PHARMA COMMERCIAL LLC$0Food and BeverageIn-kind items and services2025
2025-12-11Botanix SB Inc$29Food and BeverageIn-kind items and servicesSOFDRA Drug, DERMATOLOGY2025
2025-12-10LEO Pharma Inc.$22Food and BeverageIn-kind items and servicesADBRY Biological, DERMATOLOGY2025
2025-12-09ABBVIE INC.$17Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-12-08ABBVIE INC.$4Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2025
2025-12-04Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and servicesRhapsido Drug, Immunology2025
2025-11-24Galderma Laboratories, L.P.$14Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-11-19ABBVIE INC.$18Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-11-14LEO Pharma Inc.$23Food and BeverageIn-kind items and servicesANZUPGO Drug, DERMATOLOGY2025
2025-11-13Arcutis Biotherapeutics, Inc.$24Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-11-12Galderma Laboratories, L.P.$7Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-11-11ABBVIE INC.$18Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-11-10ABBVIE INC.$6Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-11-06ABBVIE INC.$17Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2025
2025-11-04Arcutis Biotherapeutics, Inc.$20Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-11-03ABBVIE INC.$25Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-10-30MAYNE PHARMA COMMERCIAL LLC$7Food and BeverageIn-kind items and services2025
2025-10-29Cipher Pharmaceuticals US LLC$22Food and BeverageCash or cash equivalentNatroba Drug, Antiparasitic2025
2025-10-28Regeneron Healthcare Solutions, Inc.$28Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-10-28Amgen Inc.$22Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-10-27Janssen Biotech, Inc.$16Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-10-23ABBVIE INC.$11Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-10-17Galderma Laboratories, L.P.$6Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-10-14Novartis Pharmaceuticals Corporation$19Food and BeverageIn-kind items and servicesRhapsido Drug, Immunology2025
2025-10-07ABBVIE INC.$6Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-10-03ABBVIE INC.$16Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2025
2025-09-30PFIZER INC.$14Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-09-30ABBVIE INC.$4Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-09-24Galderma Laboratories, L.P.$14Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-09-16UCB, Inc.$28Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-09-15Arcutis Biotherapeutics, Inc.$20Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-09-10Janssen Biotech, Inc.$36Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-09-09Botanix SB Inc$14Food and BeverageIn-kind items and servicesSOFDRA Drug, DERMATOLOGY2025
2025-09-03ABBVIE INC.$17Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-08-27Incyte Corporation$14Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-08-25SUN PHARMACEUTICAL INDUSTRIES INC.$30Food and BeverageIn-kind items and servicesILUMYA Biological, Dermatology2025
2025-08-25Janssen Biotech, Inc.$23Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-08-21ABBVIE INC.$1Food and BeverageIn-kind items and services2025
2025-08-13Regeneron Healthcare Solutions, Inc.$35Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-08-12Galderma Laboratories, L.P.$13Food and BeverageIn-kind items and servicesAKLIEF Drug, ACNE2025
2025-08-11Amgen Inc.$28Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-08-01PFIZER INC.$19Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-07-30Lilly USA, LLC$23Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2025
2025-07-29ABBVIE INC.$17Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-07-28LEO Pharma Inc.$18Food and BeverageIn-kind items and servicesADBRY Biological, DERMATOLOGY2025
2025-07-24ABBVIE INC.$15Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-07-23ABBVIE INC.$9Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-07-15Botanix SB Inc$18Food and BeverageIn-kind items and servicesSOFDRA Drug, DERMATOLOGY2025
2025-07-11Galderma Laboratories, L.P.$6Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-07-07Amgen Inc.$27Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-07-01UCB, Inc.$26Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-06-24ABBVIE INC.$23Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2025
2025-06-24Galderma Laboratories, L.P.$3Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-06-18Botanix SB Inc$21Food and BeverageIn-kind items and servicesSOFDRA Drug, DERMATOLOGY2025
2025-06-17Arcutis Biotherapeutics, Inc.$19Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-06-11ABBVIE INC.$16Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-06-10Lilly USA, LLC$20Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2025
2025-05-21Janssen Biotech, Inc.$21Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-05-20Arcutis Biotherapeutics, Inc.$19Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-05-16PFIZER INC.$19Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-05-15Amgen Inc.$25Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-05-07Arcutis Biotherapeutics, Inc.$19Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-05-06ABBVIE INC.$123Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2025
2025-05-01LEO Pharma Inc.$22Food and BeverageIn-kind items and servicesADBRY Biological, DERMATOLOGY2025
2025-05-01ABBVIE INC.$9Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2025
2025-04-24Regeneron Healthcare Solutions, Inc.$32Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-04-23Galderma Laboratories, L.P.$14Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-04-22Amgen Inc.$28Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-04-17Arcutis Biotherapeutics, Inc.$20Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-04-14ABBVIE INC.$9EducationIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-04-10Amgen Inc.$33Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-04-10Botanix SB Inc$24Food and BeverageIn-kind items and servicesSOFDRA Drug, DERMATOLOGY2025
2025-03-25Arcutis Biotherapeutics, Inc.$22Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-03-20PFIZER INC.$15Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-03-12Organon Llc$2Food and BeverageIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-03-11Amgen Inc.$31Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-03-06Biofrontera Inc.$20Food and BeverageIn-kind items and servicesAMELUZ Drug, DERMATOLOGY2025
2025-03-03ABBVIE INC.$13Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-02-27Galderma Laboratories, L.P.$6Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-02-26Arcutis Biotherapeutics, Inc.$22Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-02-18ABBVIE INC.$16Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-02-11Amgen Inc.$25Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-02-06Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and services2025
2025-02-04UCB, Inc.$18Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-02-03Lilly USA, LLC$20Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2025
2025-01-30LEO Pharma Inc.$20Food and BeverageIn-kind items and servicesADBRY Biological, DERMATOLOGY2025
2025-01-23Galderma Laboratories, L.P.$35Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-01-21ABBVIE INC.$23Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-01-16Arcutis Biotherapeutics, Inc.$24Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2024-12-18Arcutis Biotherapeutics, Inc.$16Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2024
2024-12-12PFIZER INC.$18Food and BeverageIn-kind items and servicesEUCRISA Drug, DERMATOLOGY2024
2024-12-10Amgen Inc.$24Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-12-09Janssen Biotech, Inc.$35Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2024
2024-12-09ABBVIE INC.$4Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-12-05Dermavant Sciences, Inc.$13Food and BeverageIn-kind items and servicesVTAMA Drug, DERMATOLOGY2024
2024-12-04SUN PHARMACEUTICAL INDUSTRIES INC.$26Food and BeverageIn-kind items and servicesWinlevi Drug, Dermatology2024
2024-12-02ABBVIE INC.$6Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-11-21UCB, Inc.$20Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2024
2024-11-20Novartis Pharmaceuticals Corporation$24Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2024
2024-11-14E.R. Squibb & Sons, L.L.C.$24Food and BeverageCash or cash equivalentSotyktu Drug, Immunology2024
2024-11-13Arcutis Biotherapeutics, Inc.$17Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2024
2024-11-06Amgen Inc.$27Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-10-31E.R. Squibb & Sons, L.L.C.$21Food and BeverageCash or cash equivalentSotyktu Drug, Immunology2024
2024-10-30ABBVIE INC.$23Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-10-28Lilly USA, LLC$27Food and BeverageIn-kind items and servicesOLUMIANT Drug, Immunology2024
2024-10-24Novartis Pharmaceuticals Corporation$6Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2024
2024-10-17ABBVIE INC.$2Food and BeverageIn-kind items and services2024
2024-10-10Amgen Inc.$29Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-10-08Incyte Corporation$17Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2024
2024-10-02Almirall LLC$19Food and BeverageIn-kind items and servicesKlisyri Drug, Dermatology2024
2024-10-01Novartis Pharmaceuticals Corporation$30Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2024
2024-09-30ABBVIE INC.$19Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2024
2024-09-26GENZYME CORPORATION$24Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2024
2024-09-25ABBVIE INC.$23Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2024
2024-09-23Galderma Laboratories, L.P.$15Food and BeverageIn-kind items and services2024
2024-09-19Amgen Inc.$26Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-09-18SUN PHARMACEUTICAL INDUSTRIES INC.$18Food and BeverageIn-kind items and servicesBLU-U Medical Supply, Dermatology2024
2024-09-17PFIZER INC.$15Food and BeverageIn-kind items and servicesEUCRISA Drug, DERMATOLOGY2024
2024-09-12LEO Pharma Inc.$28Food and BeverageIn-kind items and servicesADBRY Biological, DERMATOLOGY2024
2024-09-12Lilly USA, LLC$25Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2024
2024-09-10ABBVIE INC.$27Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-09-09ABBVIE INC.$21Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-09-05Lilly USA, LLC$17Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2024
2024-09-04Arcutis Biotherapeutics, Inc.$24Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2024
2024-08-29Lilly USA, LLC$25Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2024
2024-08-28Janssen Biotech, Inc.$15Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2024
2024-08-22Arcutis Biotherapeutics, Inc.$18Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2024
2024-08-21Amgen Inc.$31Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-08-19ABBVIE INC.$22Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-08-12Novartis Pharmaceuticals Corporation$26Food and BeverageIn-kind items and services2024
2024-08-07Incyte Corporation$22Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2024
2024-08-02ABBVIE INC.$29Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2024
2024-08-01Regeneron Healthcare Solutions, Inc.$36Food and BeverageIn-kind items and servicesDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY2024
2024-07-29Novartis Pharmaceuticals Corporation$33Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2024
2024-07-25Amgen Inc.$23Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-07-22Lilly USA, LLC$11Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2024
2024-07-17Boehringer Ingelheim Pharmaceuticals, Inc.$24Food and BeverageIn-kind items and servicesSPEVIGO Drug, IMMUNOLOGY2024
2024-07-16Janssen Biotech, Inc.$22Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2024
2024-07-10ABBVIE INC.$2Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2024
2024-07-09ABBVIE INC.$15Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-06-26Amgen Inc.$21Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-06-25ABBVIE INC.$21Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-06-24ABBVIE INC.$21Food and BeverageIn-kind items and services2024
2024-06-20PFIZER INC.$15Food and BeverageIn-kind items and servicesEUCRISA Drug, DERMATOLOGY2024
2024-06-20ABBVIE INC.$8Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-06-17ABBVIE INC.$21Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2024
2024-06-13ABBVIE INC.$28Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2024
2024-05-28ABBVIE INC.$17Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-05-21UCB, Inc.$16Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2024
2024-05-01ABBVIE INC.$21Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2024
2024-04-24ABBVIE INC.$6Food and BeverageIn-kind items and services2024
2024-04-23Novartis Pharmaceuticals Corporation$31Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2024
2024-04-22MIMEDX Group, Inc.$20Food and BeverageIn-kind items and services2024
2024-04-18Amgen Inc.$29Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-04-09PFIZER INC.$15Food and BeverageIn-kind items and servicesEUCRISA Drug, DERMATOLOGY2024
2024-03-28Incyte Corporation$21Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2024
2024-03-19Amgen Inc.$23Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-03-08Janssen Biotech, Inc.$35Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2024
2024-03-01ABBVIE INC.$23Food and BeverageIn-kind items and services2024
2024-02-27Lilly USA, LLC$24Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2024
2024-02-22Regeneron Healthcare Solutions, Inc.$34Food and BeverageIn-kind items and servicesLIBTAYO Biological, ONCOLOGY2024
2024-02-20PFIZER INC.$14Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2024
2024-02-15Amgen Inc.$24Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-02-08Novartis Pharmaceuticals Corporation$34Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2024
2024-02-06Biofrontera Inc.$24Food and BeverageCash or cash equivalentAMELUZ Drug, DERMATOLOGY2024
2024-02-02PFIZER INC.$15Food and BeverageIn-kind items and servicesEUCRISA Drug, DERMATOLOGY2024
2024-02-01PFIZER INC.$1EducationIn-kind items and servicesLITFULO Drug, IMMUNOLOGY2024
2024-01-31Incyte Corporation$19Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2024
2024-01-23Almirall LLC$17Food and BeverageIn-kind items and servicesSeysara Drug, Dermatology2024
2024-01-18Amgen Inc.$25Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2024
2024-01-17Kerecis Limited$20Food and BeverageCash or cash equivalentKerecis Omega3 SurgiClose Device, Wound Care2024
2023-12-14Amgen Inc.$21Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2023
2023-12-12SUN PHARMACEUTICAL INDUSTRIES INC.$37Food and BeverageIn-kind items and servicesILUMYA Biological, Dermatology2023
2023-12-11Janssen Biotech, Inc.$99EducationIn-kind items and servicesTREMFYA Drug, Immunology2023
2023-12-04Incyte Corporation$20Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2023
2023-12-04ABBVIE INC.$7Food and BeverageIn-kind items and services2023
2023-11-27Incyte Corporation$18Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2023
2023-11-22PFIZER INC.$11Food and BeverageIn-kind items and servicesEUCRISA Drug, DERMATOLOGY2023
2023-11-16ABBVIE INC.$29Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2023
2023-11-16ABBVIE INC.$18Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2023
2023-11-14Amgen Inc.$24Food and BeverageIn-kind items and servicesOtezla Drug, Inflammation2023
2023-11-07ABBVIE INC.$14Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2023
2023-11-06SUN PHARMACEUTICAL INDUSTRIES INC.$33Food and BeverageIn-kind items and servicesILUMYA Biological, Dermatology2023
2023-11-01Incyte Corporation$14Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2023
2023-10-31ABBVIE INC.$22Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2023
2023-10-25Janssen Biotech, Inc.$33Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2023
2023-10-20ABBVIE INC.$15Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2023
2023-10-19Janssen Biotech, Inc.$14Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2023
2023-10-10SUN PHARMACEUTICAL INDUSTRIES INC.$18Food and BeverageIn-kind items and servicesBLU-U Medical Supply, Dermatology2023
2023-10-05PFIZER INC.$5,750Research paymentCash or cash equivalentNURTEC ODT Drug, PAINA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE P2023
2023-10-04Regeneron Healthcare Solutions, Inc.$38Food and BeverageIn-kind items and servicesLIBTAYO Biological, ONCOLOGY2023
2023-09-26Regeneron Healthcare Solutions, Inc.$31Food and BeverageIn-kind items and servicesDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY2023
2023-09-25ABBVIE INC.$17Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2023
2023-09-21Arcutis Biotherapeutics, Inc.$17Food and BeverageIn-kind items and services2023
2023-09-14Biofrontera Inc.$23Food and BeverageCash or cash equivalentAMELUZ Drug, DERMATOLOGY2023
2023-09-06ABBVIE INC.$34Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2023
2023-08-30ABBVIE INC.$18Food and BeverageIn-kind items and servicesBOTOX Biological, FACIAL AESTHETICS2023

The latest 200 records of 484.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-16PFIZER INC.North Texas Center For Clinical Research$1,995A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-12-11PFIZER INC.North Texas Center For Clinical Research$2,128A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE P2025
2025-12-11Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$5,000A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-12-11Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,000A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-12-11Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,500A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-12-11Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,000A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-12-01Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$5,000A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant2025
2025-12-01Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICA$206A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W2025
2025-12-01Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,000A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant2025
2025-12-01Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,000A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant2025
2025-12-01Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,500A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant2025
2025-11-26PFIZER INC.North Texas Center For Clinical Research$5,117A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-11-06PFIZER INC.North Texas Center For Clinical Research$12,366A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE P2025
2025-11-04PFIZER INC.North Texas Center For Clinical Research$5,584A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-10-22Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICA$1,858TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-2792025
2025-10-09PFIZER INC.North Texas Center For Clinical Research$2,542A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE P2025
2025-10-09PFIZER INC.North Texas Center For Clinical Research$3,200A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-09-24PFIZER INC.North Texas Center For Clinical Research$6,630A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-09-03Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$1,593TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-2792025
2025-09-03PFIZER INC.North Texas Center For Clinical Research$8,317A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-08-05PFIZER INC.North Texas Center For Clinical Research$5,407A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-08-01Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,637A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-08-01Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$856A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-07-23Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$1,755TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-2792025
2025-07-23Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$4,181TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-2792025
2025-07-23Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$1,800TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-2792025
2025-07-11PFIZER INC.North Texas Center For Clinical Research$10,404A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-07-09Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$2,888A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W2025
2025-07-07Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$991A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-07-07Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,350A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-06-20SANOFI US SERVICES INC.North Texas Center For Clinical Research$1,000Registry to characterize the patients who receive Dupixent for PN in a real-world setting2025
2025-06-13Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$2,076TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-2792025
2025-06-04Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$991A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-06-04Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$2,304A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W2025
2025-06-04Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$2,198A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-06-04Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,458A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-06-04Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$2,209A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-06-04Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$2,209A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-06-04Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$343A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-06-04Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,086A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-29PFIZER INC.North Texas Center For Clinical Research$4,883A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-05-28Eli Lilly and CompanyNORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$8,673A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE2025
2025-05-06PFIZER INC.North Texas Center For Clinical Research$1,682A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$120A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$32A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$32A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$163A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,914A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$58A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$58A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$15A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$2,209A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$32A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-05-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,565A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-09Takeda Pharmaceuticals U.S.A., Inc.NORTH TEXAS CENTER FOR CLINICAL RESEARCH LLC$6,450A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W2025
2025-04-08PFIZER INC.North Texas Center For Clinical Research$3,157A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$32A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$32A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$32A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$2A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$58A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$3A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,611A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$120A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$58A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$609A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-04-02Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$32A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-22PFIZER INC.North Texas Center For Clinical Research$7,529A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 AND PF07262025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$25A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$343A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$2,198A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,458A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$991A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$856A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$1,914A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$2,252A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$991A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$2,252A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-03-05Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$991A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$32A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$22A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$22A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$15A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$91A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$22A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$190A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$13A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$9A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$5A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$117A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$16A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$64A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$22A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$54A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$29A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$16A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025
2025-02-06Incyte CorporationNORTH TEXAS CENTER FOR CLINICAL RESEARCH NTCCR$58A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Collin CountyProsper town

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Prosper, TX, county Collin County, TX, state Texas; placed by its city name.

MeasurePlace (city or town)
Prosper, TX
County
Collin County, TX
State
Texas
Population B0100337,8691,163,33730,188,424
Population, 2020 census P130,1741,064,46529,145,505
Median age B0100237.637.335.6
Under 18 B0100132.7%24.7%25.0%
65 and over B010019.2%11.6%13.4%
Households B1100111,239416,64610,992,816
Foreign born B0500216.9%23.3%17.6%
Median household income B19013$195,281$121,600$78,476
Median family income B19113$207,680$145,862$94,599
Per capita income B19301$72,601$57,056$40,752
Poverty rate B170015.5%6.2%13.8%
Unemployment rate B230255.6%4.2%5.3%
Civilian labor force B2302519,043642,25315,233,563
Mean commute (minutes) B0801329.528.226.7
Bachelor's degree or higher B1500366.5%56.2%33.8%
Housing units B2500111,921437,39612,128,515
Owner-occupied B2500387.9%64.5%62.6%
Renters B2500312.1%35.5%37.4%
Median home value B25077$823,700$475,600$283,800
Median gross rent B25064$2,176$1,859$1,403
White, not Hispanic B0300259.3%49.6%39.1%
Black B030027.2%10.8%11.9%
Hispanic or Latino B0300212.1%16.1%39.7%
Asian B0300214.9%18.7%5.5%
American Indian and Alaska Native B030020.2%0.2%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Prosper, TX.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.